Ultragenyx Pharmaceutical Inc. (RARE)

Ultragenyx Pharmaceutical Revenue by Segment

Period Ending	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020
Product	369.31M	339.18M	321.49M	314.47M	285.47M	265.30M	230.30M	198.70M
Product Growth	29.37%	27.85%	39.59%	58.26%	58.24%	68.34%	55.82%	45.67%
Other	303.42M	291.43M	288.69M	276.21M	274.71M	257.40M	250.90M	243.80M
Other Growth	10.45%	13.22%	15.06%	13.29%	8.24%	1.90%	2.37%	2.65%

Revenue by Geography

Period Ending	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020
North America	361.22M	354.58M	340.56M	340.46M	316.40M	307.30M	297.70M	307.10M
North America Growth	14.16%	15.39%	14.40%	10.86%	5.82%	3.05%	4.02%	9.29%
Latin America	149.83M	144.47M	150.40M	130.71M	130.30M	109.50M	89.70M	77.30M
Latin America Growth	14.99%	31.93%	67.67%	69.10%	93.32%	70.30%	55.46%	72.93%
Europe	103.33M	97.65M	87.45M	80.12M	69.60M	60.40M	54.20M	47.60M
Europe Growth	48.47%	61.68%	61.35%	68.33%	63.00%	58.53%	44.15%	30.77%
Japan	14.94M	12.89M	9.69M	-	7.60M	6.50M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Japan Growth	129.83%	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.